CMS

Our in-brief roundup of notable stories from the last week.

Effective July 2027, the rule requires PBMs to disclose rebates and other payments from drug makers, plus payments from pharmacies.

Lawmakers want answers from 10 major insurers about their role in a CMS-led effort resulting in the canceling of coverage for more than 760,000 people.

HHS announced an FDA guidance and expanded CMS payment model to help patients with rare genetic diseases.

CMS proposes requiring eligibility verification before ACA premium subsidies are granted, implementing new anti-fraud provisions for 2028.

Proposed rule would cut some low-income drug copays, tighten Medicare Advantage provider directory standards, and increase PBM oversight.

The pharma trade group claims CMS exceeded its authority with the Medicare Part B pricing model.

Medtech trade group outlines recs to improve Medicare’s proposed RAPID coverage pathway and accelerate access to FDA-authorized tech.